- Journalists Talk Hot Health Topics: Urgent Care Clinics Performing Abortions and Doulas’ Pay
- ASCs’ vendor problem
- Providence’s physician chief on its ‘holistic’ approach to value-based care
- What the Health? From KFF Health News: A New CDC Nominee, Again
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care
- Anesthesia job market faces ‘major disruption’
- Florida system raises $100M for new ED
- North Carolina system names COO
- Mark Cuban wants to bring drug manufacturing to hospitals’ doorsteps — literally
- UCI Health names chief AI officer
- Nevada hospital names CEO
- Saint Luke’s taps president for 2 hospitals
- Dental community mourns dentist killed in murder-suicide
- Mass General Brigham, CVS deal could raise healthcare spending $40M annually: Report
- Ideal Dental opens 1st Oklahoma practice, expands in 2 more states
- PDS Health eyes the next era of medical-dental integration
- Mark Cuban dives into direct contracting
- HCA executive pay by the numbers
- Iris Telehealth offers behavioral health analytics platform
- HHS names chief economist, regulatory leader to address healthcare affordability
- Loma Linda University Health names new president
- The best ASCs for colonoscopy, endoscopy in the South: US News
- Tennessee moves forward with CON repeal
- Dental schools take action to alleviate workforce shortages: 6 updates
- American Medical Group Association partners with Talkiatry to expand psych access
- Trump nominates CDC director
- ChristianaCare, Cardiovascular Physicians of Delaware to open joint venture ASC
- 5 states regulating AI in mental health
- Centerstone debuts $13M youth behavioral health campus in Missouri
- 3 DSOs making headlines
- Maine restricts noncompetes for rural healthcare workers
- Heartland Dental opens Florida office
- The 10 biggest ASC deals of the last 5 years
- Affordability, transparency: A look at large employers' top healthcare concerns
- 10 dental Medicaid updates to know from Q1
- White House eyes ibogaine research expansion
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- SocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patients
- FDA To Review Whether To Allow More Access To Certain Peptides
- Rising Colon Cancer Deaths Hit Younger Adults Without Degrees Hardest
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Over 80% of PCPs concerned about financial stability over next several years
- Industry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the program
- FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
- Most People Would Take A Blood Test For Alzheimer's, Study Says
- This Sexually Transmitted Infection Linked To Heart Attack, Stroke
- How Playtime at Age 2, Especially with Parents, Shapes Teen Fitness Habits
- New Depression Treatment Matches ECT with Less Memory Loss, Study Says
- Memory Problems? Your Salt Intake Could Make Matters Worse, Study Says
- Ultra-Processed Foods Linked To Fatty Muscles, Potential Knee Arthritis
- Your New Therapist: Chatty, Leaky, and Hardly Human
- Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
- Gen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study finds
- Listen: With Little Federal Regulation, States Are Left To Shape the Rules on AI in Health Care
- Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
- BIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthday
- The future of medical-dental integration is here
- Texas dentist has license suspended
- Efforts grow to limit corporate dental ownership, protect dentist autonomy: 6 updates
- What’s the deal with insurer mental health parity violations?
- Remarks at the Options Market Structure Roundtable
- Wider care gaps predicted as mental health parity rule faces rollback
- Sheppard Pratt gets $16.5M for behavioral health expansion
- Former Deputy Surgeon General Erica Schwartz, M.D., nominated as CDC director
- Verily Health simplifies medical jargon alphabet soup with AI-powered app in new campaign
- 10 trends in behavioral health usage: Report
- Cattywampus: Statement on the CAT Concept Release
- Providers' advantage on out-of-network billing disputes likely to continue: Capstone
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Viatris, Teva kick off separate recalls over dissolution, raw material issues
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- APA launches resource library for trusted digital mental health tools
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- Air Pollution and Weather Tied to Migraines
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- EPA Delays Decisions on 'Forever Chemicals'
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- Progyny unveils new fertility benefit option for small, mid-size employers
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Medi-Cal Immigrant Enrollment Is Dropping. Researchers Point to Trump’s Policies.
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- Hospitals with more disadvantaged patients fall short on price transparency, study finds
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- Listen to the Latest ‘KFF Health News Minute’
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- Does Your Child Have Nightmares? Here's One Solution
- Marriage's Hidden Benefit? A Lower Risk Of Cancer
- Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
- Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- Statement Regarding Staff No-Action Letter to Bank of England
Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi all signed onto Trump's Most Favored Nation plan today; the plan outlined in his July 31st letter to Big Pharma CEOs. This brings 14 of the 17 targeted Big Pharma companies into accord with MFN. AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer have previously reached MFN agreements with the Administration. AbbVie is said to be close to an MFN deal with the Administration. The status of Johnson & Johnson and Regeneron have not been publicly disclosed.
The agreement also requires $ 150 billion in domestic pharmaceutical manufacturing, research and development investment commitments from the nine companies:
Trump, nine pharmaceutical companies strike deal to cut prices
By Michael Erman, Jarrett Renshaw and Patrick Wingrove - December 19, 2025Summary
- Drugmakers to cut prices on most drugs sold to the Medicaid program
- U.S. patients pay the most for prescription medicines
Dec 19 (Reuters) - U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align U.S. costs with those in other wealthy nations.
Bristol Myers Squibb (BMY.N), Gilead Sciences (GILD.O), and Merck (MRK.N), and Roche's (ROG.S) U.S. unit Genentech have struck deals. Novartis (NOVN.S), Amgen (AMGN.O), Boehringer Ingelheim, Sanofi (SASY.PA), and GSK (GSK.L) have also signed on.
Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid program for low-income people, senior administration officials said, promising "massive savings" on widely used medicines without giving specific figures.
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
The details of each deal were not immediately available but officials said they included agreements to cut cash-pay direct-to-consumer prices of select drugs sold potentially through the TrumpRx.gov website, to launch drugs in the U.S. at prices equal to - not lower than - those in other wealthy nations and to increase manufacturing. In return, companies can receive a three-year exemption from any tariffs.
MERCK'S JANUVIA, JANUMET ON TRUMPRx
Merck said it will sell its diabetes drugs Januvia, Janumet and Janumet XR - set to face generic competition next year - directly to U.S. consumers at about 70% off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels.
Enlicitide is one of two Merck drugs expected to receive a speedy review under the FDA's new, fast-track pathway, Reuters previously reported.
In July, Trump sent letters to leaders of 17 major drugmakers, urging them to offer so-called most-favored-nation prices to Medicaid and ensure new medicines launch at prices no higher than those in other wealthy countries.
Five companies had previously struck deals with the administration to rein in prices - Pfizer, Eli Lilly (LLY.N), AstraZeneca (AZN.L), Novo Nordisk (NOVOb.CO), and EMD Serono, the U.S. division of Germany's Merck KGaA (MRCG.DE).
The remaining three that have not announced deals are Regeneron (REGN.O), Johnson & Johnson (JNJ.N), and AbbVie (ABBV.N). Investors initially feared sweeping U.S. price controls, but the details of recent deals have largely eased those concerns. Reuters previously reported that AbbVie was expected to announce a deal on Friday.
Drugmakers on Friday committed to “most-favored-nation” pricing on all new U.S. drug launches across commercial, government and cash-pay markets, including the U.S. Medicare program for those aged 65 and over, officials said.
A portion of revenues from each company's foreign sales will also be remitted to the U.S. to offset costs, officials said.
The companies pledged together to invest more than $150 billion in U.S. for R&D and manufacturing, according to officials, although it was unclear whether that included earlier commitments. Several also agreed to donate drug ingredients to the U.S. strategic reserve.
Merck said it chipped in $70 billion of that sum.Analysts have noted that Medicaid, which accounts for only around 10% of U.S. drug spending, already benefits from substantial price discounts, exceeding 80% in some cases.
Pfizer, which announced its 2026 financial outlook on Tuesday, said the Medicaid discounts would result in price and margin compression next year.
The White House Fact Sheet:
Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients
The White House
December 19, 2025LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price).
- The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
- The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.
- The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
- The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market.
- The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
- The agreements require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.
DELIVERING LOWER COSTS: Patients will be able to see massive price reductions on numerous products when purchasing directly through TrumpRx as a result of today’s actions. Select examples include:
- Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
- Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
- Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
- Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
- Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
- GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
- Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
- Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
- Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.
BOLSTERING NATIONAL HEALTH SECURITY BY INVESTING IN AMERICA: The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.
- GSK will contribute 98.8kg of albuterol, the active ingredient in a common rescue inhaler for people with asthma.
- Bristol Myers Squibb will contribute tablets representing 6.5 tons of apixaban, the active ingredient in the drug Eliquis, a blood thinner taken by millions of American patients.
- Merck will contribute 3.5 tons of ertapenem, an antibacterial medication used to treat complex infections.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 14 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines.
Johnson & Johnson disclosed their MFN agreement late yesterday evening. Regeneron and AbbVie are still outstanding::
https://thehill.com/policy/healthcare/5681535-johnson-johnson-trump-drug-prices/
Johnson & Johnson announces drug pricing deal with Trump administration
By Nathaniel Weixel - January 9, 2026Johnson & Johnson said late Thursday it will lower prices for certain prescription drugs and match the rates in other countries, becoming the latest pharmaceutical company to strike a deal with the Trump administration in exchange for tariff relief.
The New Jersey-based health conglomerate was one of the 17 companies President Trump called out last summer to lower drug prices as part of his administration’s “most favored nation” push.
Drugmakers have been eager to strike voluntary deals to avoid punitive actions such as tariffs that could cut deeply into their profits. The only companies who received letters that have yet to strike deals with the administration are AbbVie and Regeneron.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation,” Joaquin Duato, chair and chief executive of Johnson & Johnson, said in a statement.
Under the agreement, J&J will offer specific drugs for sale directly to consumers at significant discounts through the Trump administration’s forthcoming TrumpRx website. It will also offer its drugs to the Medicaid program at comparable prices to other developed countries. The company did not say which drugs were part of the agreement.
J&J also did not specify how long its tariff reprieve will be, saying the specific terms remain confidential.
The agreement follows similar deals the administration has already made with pharma companies like Amgen, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Genentech and Sanofi.
J&J also said it is planning two new U.S. manufacturing facilities as part of a previously announced $55 billion investment: a cell therapy manufacturing site in Pennsylvania and a drug product manufacturing facility in North Carolina.
The company said construction is progressing on a $2 billion biologics manufacturing facility in Wilson, N.C., which will create about 5,000 skilled jobs in the state.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
J & DE Family Charitable Fund
Friends
of MHF
Kelly Grotendiek
Philip Harbach
Dale Johnson
Drs. Jeffrey and Joni Jones
Vickie Kahle
Tammy Kipen
Marlin & Kathy Klumpp
Melanie Kurdys
Ruth Nobel
Patrick Peterson
Stephanie Poortenga
Jeanne Smit
Ben and Hope Staal
John Tuinstra
Jacki VanHuis
Sandy Walker
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
